Connect with others who understand.

sign up log in
About mySMAteam
Powered By


Evrysdi is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat people with spinal muscular atrophy (SMA) ages 2 months and older. Evrysdi is also known by its drug name, Risdiplam.

Evrysdi is a survival motor neuron 2 (SMN2) splicing modifier. It is believed to increase the production of full-length SMN, a protein which is deficient in people with SMA due to an inactivating gene mutation. SMN normally functions in important cellular processes, including DNA to RNA conversion and moving materials into and out of cells.

How do I take it?

Evrysdi is taken orally once a day after a meal, using an oral syringe provided by a physician.

Side effects

The FDA-approved label for Evrysdi lists common side effects experienced by people with later-onset SMA, including fever, diarrhea, and rash. For those with infantile-onset SMA, common side effects include fever, diarrhea, rash, upper respiratory tract infection, pneumonia, constipation, and vomiting.

If you are pregnant or planning to become pregnant, consult your doctor before taking Evrysdi, as this drug may cause fetal harm.

For more details about this treatment, visit:

Evrysdi — Genentech

Already a Member? Log in